Contents
Academy · Research Writing · Clinical Study Report
The Clinical Study Report: ICH E3 Structure and Its Relationship to the Journal Manuscript
A clinical study report (CSR) is not a shorter version of the journal manuscript. It is the complete, regulator-facing account from which the manuscript is written, and the two documents are expected to report the same findings at very different levels of detail.
A clinical study report (CSR) is the comprehensive document describing the methods and results of a single clinical trial, structured to a fixed, internationally harmonised format (ICH E3) so that regulatory agencies can fully assess a trial's design, conduct, statistical analysis and findings as part of a marketing authorisation submission.
Learning objectives
- What ICH E3 is, and why the CSR format is standardised rather than left to each sponsor.
- How a CSR's scope and audience differ from a journal manuscript reporting the same trial.
- The main structural sections of an ICH E3 CSR and what each must contain.
- Why consistency between a CSR and its related journal manuscript matters, and where the two are expected to differ.
Common misconceptions
- “A CSR is just a longer journal article about the same trial.” A CSR follows a fixed, regulator-defined structure (ICH E3) designed for complete regulatory assessment, including full statistical analysis detail and appendices that a journal manuscript does not contain; a manuscript is a condensed, audience-adapted account derived from the CSR, not the reverse.
- “Every sponsor can structure a CSR however suits their trial.” ICH E3 defines a harmonised structure specifically so that regulators reviewing CSRs from different sponsors and trials can locate the same category of information in a predictable place.
- “A CSR and the published manuscript of the same trial should match word for word.” They are expected to be consistent in their reported findings but may legitimately differ in length, level of statistical detail and audience-appropriate framing; what must match is the substance (the methods, numbers and conclusions), not the prose.
ICH E3 and the standardisation of the CSR format
The International Council for Harmonisation guideline E3, Structure and Content of Clinical Study Reports, sets out the harmonised format that regulatory agencies in ICH member regions expect a CSR to follow. The stated purpose of the guideline is to help ensure that a CSR provides, in one document, a sufficiently complete account of a trial’s design, conduct and results for a regulatory reviewer to assess it without separately requesting the underlying data for routine review. Standardising the structure across sponsors and trials enables a regulatory reviewer who assesses CSRs from many sponsors to locate a given category of information (for example, a particular safety analysis) in a predictable section, regardless of which company or trial produced the report.
Differences between a CSR and a journal manuscript
A CSR and a journal manuscript reporting the same trial serve different purposes for different audiences, and this difference directly determines their length and content. A CSR is written for a regulatory reviewer who must independently assess every methodological and statistical decision; it therefore includes the full statistical methodology, complete safety data (not only the subset judged most clinically important) and extensive appendices (such as individual patient listings, full statistical analysis plans and case report form annotations). A journal manuscript, written for a clinical readership within a journal’s length limits, necessarily condenses this material into the findings and methodological detail that a practising clinician or researcher requires to interpret and apply the result. Reporting guidelines such as CONSORT govern what the manuscript must disclose at that condensed scale; ICH E3 governs what the CSR must disclose at full regulatory scale.
The main structural sections of an ICH E3 CSR
An ICH E3 CSR follows a fixed section structure, including (among its major divisions) a synopsis; an introduction and study objectives; the investigational plan (overall design, discussion of design including choice of control, selection of population, treatments, efficacy and safety variables, and statistical methods planned); the study population (disposition, protocol deviations, demographic and baseline characteristics); efficacy evaluation; safety evaluation (extent of exposure, adverse events, deaths, laboratory findings); and a discussion and overall conclusions, followed by extensive appendices. Each section enables a regulatory reviewer to trace a reported result to the exact population definition, to distinguish what was planned in advance from what was decided post hoc, and to examine the complete safety profile, not only the principal finding.
Required consistency and permissible differences between a CSR and its manuscript
Because a journal manuscript is typically written after, and derived from, the CSR of the same trial, regulators and journal editors both expect the two documents to be consistent in substance: the same population definition, the same pre-specified primary and secondary endpoints, the same key efficacy and safety findings, and the same overall conclusion. What may legitimately differ is scale and framing: the statistical methods section of the manuscript will be a fraction of that of the CSR, safety reporting will be summarised rather than exhaustively tabulated, and appendices will not be reproduced. A manuscript that reports a different population, a different primary endpoint or a materially different conclusion from the CSR of the same trial presents a reporting-consistency problem, regardless of which document is technically correct.
Key points
Key points
A clinical study report is the complete, ICH E3-structured, regulator-facing account of a single trial, designed for full independent assessment rather than for a clinical readership; a journal manuscript of the same trial is a condensed, differently structured document that must match the CSR in substance (population, endpoints, findings and conclusions), even though it differs substantially in length and detail.
Practical application
Practical application
- The CSR should be built to the ICH E3 structure from the outset rather than adapted retrospectively. The investigational-plan, population, efficacy and safety sections should be planned against the ICH E3 template from early in trial close-out, so that the statistical analysis plan and output tables map directly onto the expected sections.
- Any related manuscript should be drafted from the finalised CSR, not in parallel with it. Scheduling manuscript drafting after CSR finalisation, and drawing explicitly on the CSR’s population definitions and pre-specified endpoints, is the most reliable means of avoiding inconsistency between the two documents.
- Population, endpoints and conclusions should be cross-checked explicitly before either document is submitted. An explicit side-by-side comparison of the population definition, primary and secondary endpoints, key results and overall conclusion should be conducted between the CSR and any manuscript, rather than consistency being assumed because the same underlying data were used.
Frequently asked questions
Regulatory reviewers assessing a marketing authorisation application are the primary intended readers; CSRs are also used internally by sponsors for safety and efficacy review and may be referenced in post-authorisation activities.
Increasingly, regulators such as the European Medicines Agency have policies for proactive publication of CSRs (often with personal and commercially confidential information redacted), though practice and timing vary by agency and jurisdiction.
ICH E3 is specifically written for trials intended to support a marketing authorisation submission; the level of detail and formality expected for trials not intended for that purpose may be scoped differently, though many sponsors use the same structure for consistency across their trial portfolio.
References
- International Council for Harmonisation. ICH Harmonised Guideline E3: Structure and Content of Clinical Study Reports. read 10 October 2026. View ICH E3 guideline (PDF)
- International Council for Harmonisation. ICH E3 Questions and Answers (R1). read 10 October 2026. View ICH E3 Q&A (PDF)
Every source above is a peer-reviewed article, a publisher’s record of one, or a standard issued by the body that owns it. Each carries the date it was last read. Where a standard moves, this article is revised rather than left up with a note.
How to cite this article
Pick your referencing style and copy it. Your university or target journal may vary the punctuation — check its guide if it has one.
Pubrica Academy. (2026, October 10). The Clinical Study Report: ICH E3 Structure and Its Relationship to the Journal Manuscript. Pubrica. https://pubrica.com/academy/concepts-definitions/clinical-study-report/
Pubrica Academy. “The Clinical Study Report: ICH E3 Structure and Its Relationship to the Journal Manuscript.” Pubrica, 10 Oct. 2026, pubrica.com/academy/concepts-definitions/clinical-study-report/.
Pubrica Academy (2026) The Clinical Study Report: ICH E3 Structure and Its Relationship to the Journal Manuscript. Pubrica. Available at: https://pubrica.com/academy/concepts-definitions/clinical-study-report/ (Accessed: 15 October 2026).
Pubrica Academy. “The Clinical Study Report: ICH E3 Structure and Its Relationship to the Journal Manuscript.” Pubrica. October 10, 2026. https://pubrica.com/academy/concepts-definitions/clinical-study-report/
Pubrica Academy, ‘The Clinical Study Report: ICH E3 Structure and Its Relationship to the Journal Manuscript’ (Pubrica, 10 October 2026) <https://pubrica.com/academy/concepts-definitions/clinical-study-report/> accessed 15 October 2026.
Pubrica Academy. The Clinical Study Report: ICH E3 Structure and Its Relationship to the Journal Manuscript. [Internet]. Pubrica; 2026 Oct 10 [cited 2026 Oct 15]. Available from: https://pubrica.com/academy/concepts-definitions/clinical-study-report/
Pubrica Academy, “The Clinical Study Report: ICH E3 Structure and Its Relationship to the Journal Manuscript,” Pubrica, Oct. 10, 2026. [Online]. Available: https://pubrica.com/academy/concepts-definitions/clinical-study-report/
@misc{clinical_study_report_2026,
author = {{Pubrica Academy}},
title = {The Clinical Study Report: ICH E3 Structure and Its Relationship to the Journal Manuscript},
howpublished = {Pubrica},
year = {2026},
month = {oct},
url = {https://pubrica.com/academy/concepts-definitions/clinical-study-report/},
note = {Accessed: <span data-cite-acc="iso">2026-10-15</span>}
}This article is written to be learned from. Cite it if you are referring to what it says; if you are using the evidence behind it, cite the sources listed above instead.
CSR-to-manuscript consistency check stub
To be completed before submission of a manuscript derived from a finalised CSR.
Population definition matches CSR? Y/N ____ Primary endpoint matches pre-specified CSR definition? Y/N ____ Secondary endpoints matching CSR? Y/N ____ Key efficacy results consistent with CSR tables? Y/N ____ Safety summary consistent with CSR safety section? Y/N ____ Overall conclusion consistent with CSR discussion? Y/N ____
Pubrica AcademyWritten and maintained by Pubrica’s subject matter experts. Articles are revised when the underlying standards change, and each article states the date on which it was last reviewed.
How Pubrica can help
The Pubrica regulatory-writing team builds clinical study reports to the ICH E3 structure and drafts related manuscripts directly from the finalised CSR, with an explicit consistency check on population, endpoints, findings and conclusions before either document is submitted.